Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of cisplatin-induced delayed emesis
2008-001339-37Phase 3Active
- Sponsor
- Azienda Ospedaliera Santa Maria di Terni
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Azienda Ospedaliera Santa Maria di Terni. Primary endpoint: Complete response rate for delayed emesis (days 2–5). Started Aug 2009; status: active.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2008-001339-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001339-37.